Literature DB >> 33567477

Estimation and modeling of the restricted mean time lost in the presence of competing risks.

Sarah C Conner1, Ludovic Trinquart1.   

Abstract

Survival data with competing or semi-competing risks are common in observational studies. As an alternative to cause-specific and subdistribution hazard ratios, the between-group difference in cause-specific restricted mean times lost (RMTL) gives the mean difference in life expectancy lost to a specific cause of death or in disease-free time lost, in the case of a nonfatal outcome, over a prespecified period. To adjust for covariates, we introduce an inverse probability weighted estimator and its variance for the marginal difference in RMTL. We also introduce an inverse probability of censoring weighted regression model for the RMTL. In simulation studies, we examined the finite sample performance of the proposed methods under proportional and nonproportional subdistribution hazards scenarios. We illustrated both methods with competing risks data from the Framingham Heart Study. We estimated sex differences in atrial fibrillation (AF)-free times lost over 40 years. We also estimated sex differences in mean lifetime lost to cardiovascular disease (CVD) and non-CVD death over 10 years among individuals with AF.
© 2021 John Wiley & Sons, Ltd.

Entities:  

Keywords:  competing risks; cumulative incidence; restricted mean survival; restricted mean time lost; survival analysis

Mesh:

Year:  2021        PMID: 33567477      PMCID: PMC8889377          DOI: 10.1002/sim.8896

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  32 in total

1.  Predicting the restricted mean event time with the subject's baseline covariates in survival analysis.

Authors:  Lu Tian; Lihui Zhao; L J Wei
Journal:  Biostatistics       Date:  2013-11-29       Impact factor: 5.899

Review 2.  A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions.

Authors:  Aurelien Latouche; Arthur Allignol; Jan Beyersmann; Myriam Labopin; Jason P Fine
Journal:  J Clin Epidemiol       Date:  2013-02-14       Impact factor: 6.437

3.  Covariate adjustment of cumulative incidence functions for competing risks data using inverse probability of treatment weighting.

Authors:  Anke Neumann; Cécile Billionnet
Journal:  Comput Methods Programs Biomed       Date:  2016-03-10       Impact factor: 5.428

4.  G-estimation of structural nested restricted mean time lost models to estimate effects of time-varying treatments on a failure time outcome.

Authors:  Yasuhiro Hagiwara; Tomohiro Shinozaki; Yutaka Matsuyama
Journal:  Biometrics       Date:  2019-12-26       Impact factor: 2.571

5.  Constructing inverse probability weights for marginal structural models.

Authors:  Stephen R Cole; Miguel A Hernán
Journal:  Am J Epidemiol       Date:  2008-08-05       Impact factor: 4.897

6.  Doubly robust survival trees.

Authors:  Jon Arni Steingrimsson; Liqun Diao; Annette M Molinaro; Robert L Strawderman
Journal:  Stat Med       Date:  2016-03-31       Impact factor: 2.373

7.  Novel Risk Modeling Approach of Atrial Fibrillation With Restricted Mean Survival Times: Application in the Framingham Heart Study Community-Based Cohort.

Authors:  Laila Staerk; Sarah R Preis; Honghuang Lin; Juan P Casas; Kathryn Lunetta; Lu-Chen Weng; Christopher D Anderson; Patrick T Ellinor; Steven A Lubitz; Emelia J Benjamin; Ludovic Trinquart
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-03-31

Review 8.  Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.

Authors:  Ludovic Trinquart; Justine Jacot; Sarah C Conner; Raphaël Porcher
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

9.  On the empirical choice of the time window for restricted mean survival time.

Authors:  Lu Tian; Hua Jin; Hajime Uno; Ying Lu; Bo Huang; Keaven M Anderson; L J Wei
Journal:  Biometrics       Date:  2020-02-26       Impact factor: 2.571

View more
  2 in total

1.  p53 Immunohistochemistry to Identify Very High-risk Primary Prostate Cancer: A Prospective Cohort Study with Three Decades of Follow-up.

Authors:  Konrad H Stopsack; Daniela Correia Salles; J Bailey Vaselkiv; Sydney T Grob; Lorelei A Mucci; Tamara L Lotan
Journal:  Eur Urol Oncol       Date:  2021-12-27

2.  Counterfactual mediation analysis in the multistate model framework for surrogate and clinical time-to-event outcomes in randomized controlled trials.

Authors:  Isabelle R Weir; Jennifer R Rider; Ludovic Trinquart
Journal:  Pharm Stat       Date:  2021-08-04       Impact factor: 1.894

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.